سعر ايمفينزي 120مجم2.4مل محلول وريد فيال 2026

Imfinzi (durvalumab) 120 mg/2.4 ml concentrate for intravenous infusion, single vial; a PD-L1 blocking antibody used mainly in lung cancer.

• Non-small cell lung cancer: resectable NSCLC (neoadjuvant with platinum chemotherapy then adjuvant); unresectable stage III NSCLC after chemoradiation; metastatic NSCLC with tremelimumab and platinum chemotherapyPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Small cell lung cancer: limited-stage SCLC after chemoradiation; first-line extensive-stage SCLC with etoposide and carboplatin or cisplatinPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Locally advanced or metastatic biliary tract cancer with gemcitabine and cisplatin, ; the US label also covers unresectable hepatocellular carcinoma (with tremelimumab), dMMR endometrial cancer, bladder cancer and resectable gastric/GEJ adenocarcinomaPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• As a single agent in unresectable stage III NSCLC, most common (>=20%): cough, fatigue, pneumonitis/radiation pneumonitis, upper respiratory tract infections, dyspnea and rash.International label, same product · DailyMed (U.S. National Library of Medicine)
• With platinum-based chemotherapy in extensive-stage SCLC, most common (>=20%): nausea, fatigue/asthenia and alopecia.International label, same product · DailyMed (U.S. National Library of Medicine)

• The US label lists no contraindications.International label, same product · DailyMed (U.S. National Library of Medicine)

• Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system (pneumonitis, colitis, hepatitis, endocrinopathies, dermatologic reactions, nephritis, pancreatitis, solid organ transplant rejection); withhold or permanently discontinue depending on severity.International label, same product · DailyMed (U.S. National Library of Medicine)
• Infusion-related reactions: interrupt, slow or permanently discontinue the infusion depending on severity.International label, same product · DailyMed (U.S. National Library of Medicine)
• Fatal and other serious complications can occur in patients receiving allogeneic hematopoietic stem cell transplantation before or after a PD-1/PD-L1 blocking antibody.International label, same product · DailyMed (U.S. National Library of Medicine)

• Based on animal data and mechanism of action, can cause fetal harm (premature delivery, fetal loss and premature neonatal death in monkeys); human IgG1 crosses the placenta.International label, same product · DailyMed (U.S. National Library of Medicine)
• No data on durvalumab in human milk; maternal IgG is present in milk. Advise not to breastfeed during treatment and for 3 months after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)

• Durvalumab: Binds PD-L1 and blocks its interaction with PD-1 and CD80, releasing PD-L1-mediated inhibition of the anti-tumor immune response.